Literature DB >> 11174710

Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years.

H Nave1, E Mössinger, H Feist, H Lang, H Raab.   

Abstract

BACKGROUND: The heterogeneous nature of carcinoid tumors makes it difficult to develop a standardized treatment strategy for the primary tumor itself and for probable liver metastases. However, prolongation of the 5-year survival rate (5-ysr) and amelioration of the incapacitating symptoms after resection of the primary tumor and its metastases demonstrate that surgical intervention must be the treatment of choice in these tumors.
METHODS: The data of 31 patients (17 patients with midgut carcinoids, 10 patients with an endocrine carcinoma (carcinoid) of the pancreas, and 4 patients with carcinoids of the lung) who underwent liver operation for metastatic carcinoid tumors between 1983 and 1996 were analyzed, with special regard to factors influencing postoperative survival.
RESULTS: Ten patients underwent curative resection (5-ysr, 86%), and palliative operations were performed in 21 patients (5-ysr, 26%). The overall 5-ysr was 47%, with a mean postoperative follow-up of 3.5 years (range, 4 months to 10.8 years). Postoperative morbidity rate was 13%. Size of liver metastases, radicality of the operation and localization of the primary tumor were factors influencing postoperative survival.
CONCLUSIONS: Surgery for metastatic carcinoid tumors may be curative or palliative, with a potential for cure in some cases and prolongation of survival and amelioration of symptoms in the majority of patients.

Entities:  

Mesh:

Year:  2001        PMID: 11174710     DOI: 10.1067/msy.2001.110426

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  37 in total

Review 1.  Surgical treatment of gastrointestinal neuroendocrine tumors.

Authors:  Volker Fendrich; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-02-01       Impact factor: 3.445

2.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

3.  Palliative management strategies of advanced gastrointestinal carcinoid neoplasms.

Authors:  Paola Sartori; Chiara Mussi; Carlo Angelini; Stefano Crippa; Roberto Caprotti; Franco Uggeri
Journal:  Langenbecks Arch Surg       Date:  2005-06-21       Impact factor: 3.445

Review 4.  When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations.

Authors:  Mickaël Lesurtel; David M Nagorney; Vincenzo Mazzaferro; Robert T Jensen; Graeme J Poston
Journal:  HPB (Oxford)       Date:  2014-03-17       Impact factor: 3.647

5.  Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience.

Authors:  Emin Kose; Bora Kahramangil; Husnu Aydin; Mustafa Donmez; Hideo Takahashi; Federico Aucejo; Allan Siperstein; Eren Berber
Journal:  Surg Endosc       Date:  2019-04-03       Impact factor: 4.584

6.  Associated liver and multivisceral resections: should we extend the frontiers of resectability?

Authors:  Martin de Santibañes; Agustin Dietrich; Virginia Cano Busnelli; Juan Pekolj; Guillermo Ojea Quintana; Eduardo de Santibañes
Journal:  Updates Surg       Date:  2015-02-17

7.  Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies.

Authors:  Stefano Bacchetti; Enrico Maria Pasqual; Serena Bertozzi; Ambrogio P Londero; Andrea Risaliti
Journal:  Gland Surg       Date:  2014-11

Review 8.  Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.

Authors:  Skye C Mayo; Joseph M Herman; David Cosgrove; Nik Bhagat; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-10-11       Impact factor: 6.113

9.  Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors.

Authors:  D Gomez; H Z Malik; A Al-Mukthar; K V Menon; G J Toogood; J P A Lodge; K R Prasad
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 10.  [Indications and operative procedures for neuroendocrine liver metastases].

Authors:  T J Musholt; H Lang
Journal:  Chirurg       Date:  2009-02       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.